propafenone hydrochloride 300mg film-coated tablets
accord healthcare limited - propafenone hydrochloride - film-coated tablet - 300 milligram(s) - antiarrhythmics, class ic; propafenone
propafenone hydrochloride 150mg film-coated tablets
accord healthcare limited - propafenone hydrochloride - film-coated tablet - 150 milligram(s) - antiarrhythmics, class ic; propafenone
propafenone tablet
sanis health inc - propafenone hydrochloride - tablet - 150mg - propafenone hydrochloride 150mg - class ic antiarrythmics
propafenone tablet
sanis health inc - propafenone hydrochloride - tablet - 300mg - propafenone hydrochloride 300mg - class ic antiarrythmics
propafenone hydrochloride tablet film coated
bryant ranch prepack - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg
propafenone hcl hydrochloride tablet film coated
avera mckennan hospital - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 225 mg
propafenone hydrochloride tablet film coated
cardinal health - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg
propafenone hydrochloride tablet film coated
mylan institutional inc. - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg
propafenone hydrochloride capsule, extended release
american health packaging - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hcl extended release capsules, usp are indicated to prolong the time to recurrence of symptomatic atrial fibrillation (af) in patients with episodic (most likely paroxysmal or persistent) af who do not have structural heart disease. usage considerations: - the use of propafenone er capsules in patients with permanent af or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (psvt) has not been evaluated. do not use propafenone er capsules to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the functional atrioventricular (av) nodal refractory period is recommended. - the effect of propafenone on mortality has not been determined [see boxed warning ]. propafenone er capsules are contraindicated in the following circumstances: - heart failure - cardiogenic shock - sinoatrial, atrioventricular
propafenone hydrochloride capsule, extended release
northstar rx llc - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride extended-release capsules are indicated to prolong the time to recurrence of symptomatic atrial fibrillation (af) in patients with episodic (most likely paroxysmal or persistent) af who do not have structural heart disease. usage considerations: propafenone hydrochloride extended-release capsules are contraindicated in the following circumstances: risk summary in the absence of studies in pregnant women, available data from published case reports and several decades of post-marketing experience with use of propafenone hydrochloride extended-release capsules in pregnancy have not identified any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. untreated arrhythmias during pregnancy may pose a risk to the pregnant woman and fetus (see clinical considerations). propafenone and its metabolite, 5-oh-propafenone, cross the placenta in humans. in animal studies, propafenone was not teratogenic. at maternally toxic doses (ranging from 2 to 6 times t